Skip to main content

Table 5 Model-derived means and tests assessing the changes in hepatic fibrosis: the main effects and interactions

From: The effect of bone marrow-derived mesenchymal stem cell co-transplantation with hematopoietic stem cells on liver fibrosis alleviation and survival in patients with class III β-thalassemia major

Model Variable Pre-HSCT Post-HSCT Δ (se) P value
Model 1: Time Ferritin 2555.47 (239.82) 1995.70 (239.82) − 559.77 (339.15) 0.101
AST 29.06 (1.169) 29.04 (1.169) −0.02 (1.65) 0.99
ALT 37.67 (1.58) 40.08 (1.58) 2.41 (2.24) 0.282
FibroScan score 7.40 (0.38) 9.06 (0.38) 1.66 (0.54) 0.0025
Hepatic T2* MRI 19.42 (1.31) 17.43 (1.31) −1.99 (1.85) 0.283
Liver stage 1.78 (0.11) 1.62 (0.11) −0.16 (0.15) 0.297
Liver grade 2.37 (0.13) 2.53 (0.13) 0.15 (0.19) 0.412
Liver iron dry weight 10.22 (0.71) 8.17 (0.71) −2.05 (1.01) 0.0442
Model 2: Time*Intervention Variable Pre-HSCT Post-HSCT Δ (se) P value
Without mesenchyme With mesenchyme Without mesenchyme With mesenchyme
Ferritin 2835.04 (405.78) 2404.04 (308.50) 2305.80 (419.24) 1826.65 (296.44) 48.16a (347.49) 0.89
AST 29.30 (1.97) 28.90 (1.50) 28.65 (2.03) 29.27 (1.45) −1.02a (1.92) 0.596
ALT 37.41 (2.67) 40.20 (2.74) 37.79 (2.02) 40.02 (1.96) 0.55a (2.68) 0.837
FibroScan score 7.46 (0.64) 7.36 (0.49) 9.19 (0.66) 8.99 (0.47) −0.10a (0.68) 0.881
Hepatic T2* MRI 19.55 (2.21) 16.31 (1.67) 21.91 (2.27) 18.04 (1.62) −0.63a (2.21) 0.775
Liver stage 1.98 (0.18) 1.66 (0.14) 1.72 (0.19) 1.56 (0.13) 0.16a (0.24) 0.518
Liver grade 2.42 (0.22) 2.34 (0.17) 2.49 (0.23) 2.55 (0.16) 0.14a (0.36) 0.689
Liver iron dry weight 8.11 (1.22) 11.37 (0.90) 6.36 (1.23) 9.14 (0.89) −0.47a (0.93) 0.613
  1. Mixed-effect linear regression models adjusted for patient’s age, sex matching, ABO matching, source of HSCT, aGvHD, cGvHD, ferritin, and dry iron liver
  2. Se standard error
  3. aΔD = (post-HSCT-positive mesenchymal − pre-HSCT-positive mesenchymal) − (post-HSCT-negative mesenchymal − pre-HSCT-negative mesenchymal)